Advertisement
Canada markets open in 2 hours 5 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7326
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    84.14
    +0.57 (+0.68%)
     
  • Bitcoin CAD

    87,705.70
    +670.20 (+0.77%)
     
  • CMC Crypto 200

    1,385.05
    -11.48 (-0.82%)
     
  • GOLD FUTURES

    2,358.30
    +15.80 (+0.67%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,757.00
    +189.50 (+1.08%)
     
  • VOLATILITY

    15.58
    +0.21 (+1.37%)
     
  • FTSE

    8,118.79
    +39.93 (+0.49%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6821
    0.0000 (0.00%)
     

Analyst Recommendations for Exelixis in August

Analyst Recommendations for Exelixis in August

In the second quarter, Exelixis’s (EXEL) cabozantinib franchise generated revenues of $145.8 million, which was a ~66% YoY (year-over-year) growth. Exelixis’s net product revenues grew 9% sequentially in the second quarter. In the second quarter, Ipsen, Exelixis’s partner, generated cumulative revenues of $150 million from sales of cabozantinib.